NCT01963988

Brief Summary

On the EAU (European Association of Urology) guidelines, the ulcer type bladder pain syndrome (BPS) should be treated with transurethral resection (TUR) or coagulation (TUC) of ulcer. But, Up to date, there was no study to compare the therapeutic efficacy of TUR with TUC in ulcer type BPS patients. We assume TUR have a more therapeutic effect than TUC.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
126

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jun 2012

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2012

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

July 15, 2013

Completed
3 months until next milestone

First Posted

Study publicly available on registry

October 17, 2013

Completed
4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2017

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2017

Completed
Last Updated

December 14, 2017

Status Verified

December 1, 2017

Enrollment Period

5.3 years

First QC Date

July 15, 2013

Last Update Submit

December 13, 2017

Conditions

Keywords

Bladder Pain SyndromeTransurethral Resection of UlcerTransurethral Coagulation of Ulcer

Outcome Measures

Primary Outcomes (1)

  • Recurrence-free survival between TUC and TUR

    Until 12 months after the last subject be enrolled

Secondary Outcomes (6)

  • The change of voiding dairy parameters(mean number of micturition,Urgency etc) after each treatment

    1,3,6,9 and 12 months

  • The change of Pelvic Pain and Urgency/Frequency Patient Symptom Scale (PUF)

    1,3,6,9 and 12months.

  • The change of Global Response Assessment(GRA) score

    1,3,6,9 and 12 months

  • The change of EQ-5D (EuroQOL five dimensions) Health Questionnaire score

    1,3,6,9 and 12months

  • The change of Patient Global Assessment(PGA)

    12months

  • +1 more secondary outcomes

Study Arms (2)

Transurethral Coagulation (TUC)

This cohort patients will be managed with Transurethral Coagulation (TUC) of IC ulcer lesion

Procedure: Transurethral Coagulation (TUC)

Transurethral Resection(TUR)

This cohort patients will be managed with transurethral resection(TUR) of IC ulcer lesion

Procedure: Transurethral Resection(TUR)

Interventions

Transurethral Coagulation (TUC)
Transurethral Resection(TUR)

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients will be enrolled diagnosed with bladder pain syndrome by ESSIC proposal.

You may qualify if:

  • Male and female aged 18 yrs or greater
  • Patients diagnosed with BPS(Bladder Pain Syndrome)
  • Symptom persisted more than 6 months
  • Pain VAS ≥4
  • O'Leary-Sant Interstitial Cystitis questionnaire (IC-Q) scores 12 or greater with pain and nocturia domain scores \> 2.
  • Pelvic Pain and Urgency/Frequency Patient Symptom Scale(PUF) \>13
  • No history of cystoscopy within 2yrs.

You may not qualify if:

  • History of augmentation cystoplasty or previous transurethral coagulation/resection due to BPS
  • Child-bearing potential, pregnant or nursing women.
  • Mean voided volume lesser than 40ml or over than 400ml.
  • Hematuria exceeds 1+ in the urinary dipstick (dipstick) examination.
  • Urinary tract infection during run-in periods.
  • Genitourinary tuberculosis or bladder,urethral and prostate cancer
  • Recurrent urinary tract infection
  • History of hysterectomy,mid-urethral sling,pelvic organ prolapse repair,vaginal delivery or Cesarean section,prostate operation or treatment etc within 6months.
  • Neurologic disease history of cerebral infarction,multiple sclerosis or parkinsonism etc.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Samsung Medical Center

Seoul, 135-710, South Korea

Location

MeSH Terms

Conditions

Cystitis, Interstitial

Condition Hierarchy (Ancestors)

CystitisUrinary Bladder DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
professor,MD,PhD

Study Record Dates

First Submitted

July 15, 2013

First Posted

October 17, 2013

Study Start

June 1, 2012

Primary Completion

October 1, 2017

Study Completion

December 1, 2017

Last Updated

December 14, 2017

Record last verified: 2017-12

Locations